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Abstract
Pseudohypoparathyroidism 1B (PHP1B) is caused by maternal epigenetic defects in the imprinted 
GNAS cluster. PHP1B can follow an autosomal dominant mode of inheritance or occur 
sporadically (spor-PHP1B). These latter patients present broad methylation changes of two or 
more differentially methylated regions (DMR) that, when mimicking the paternal allele, raises the 
suspicious of the occurrence of paternal uniparental disomy of chromosome 20 (upd(20)pat).
A cohort of 33 spor-PHP1B patients was screened for upd(20)pat using comparative genomic 
hybridization with SNP-chip. Methylation analyses were assessed by methylation specific-
multiplex ligation-dependent probe amplification. Upd(20)pat was identified in 6 patients, all 
exhibiting typical paternal methylation pattern compared to normal controls, namely a complete 
loss of methylation of GNAS A/B:TSS-DMR, negligible methylation at GNAS-AS1 :TSS-DMR 
and GNAS-XL:Ex1-DMR and complete gain of methylation at GNAS-NESP:TSS-DMR. The 
overall frequency of upd(20) is 18% in our cohort when searched considering both severe and 
partial loss of imprinting. However, twenty five patients displayed severe methylation pattern and 
the upd(20)pat frequency reaches 24% when searching in this group. Consequently, up to day, 
upd(20)pat is the most common anomaly than other genetic alterations in spor-PHP1B patients.
Upd(20)pat occurrence is not linked to the parental age in contrast to upd(20)mat, strongly 
associated with an advanced maternal childbearing age.
This study provides criteria to guide further investigations for upd(20)pat needed for an adequate 
genetic counseling.
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1. Introduction
GNAS gene encodes the stimulatory guanine nucleotide-binding protein (Gas) and maps to 
20q13.2–13.3, a complex locus subjected to parent-specific methylation. Molecular variant 
at GNAS lead to a wide spectrum of phenotypes depending on the parental localization of 
the genetic defect [1,2]. Heterozygous inactivating GNAS mutations are the cause of 
pseudohypoparathyroidism type 1a (PHP1A: OMIM N°103580), a syndrome characterized 
by multi-hormonal resistance and Albright Hereditary Osteodystrophy (AHO), when 
maternally inherited or PseudoPseudoHypoParathyroidism (PPHP: OMIM N°300800) or 
Progressive Osseous Heteroplasia (POH: OMIM N°166350) [3,4] when paternally inherited. 
As with PHP1A, patients affected by pseudohypoparathyroidism type 1B (PHP1B) develop 
resistance to PTH leading to hypocalcemia and hyperphosphatemia, which is often 
associated with resistance to TSH and occasionally with features of AHO. PHP1B patients 
don’t carry variations in the GNAS exons coding Gas, but methylation changes at one or 
several differential methylated regions (DMRs) including at least GNAS A/B:TSS-DMR.
The GNAS locus gives rise to several different transcripts expressed from upstream 
promoters/first exons that show, with the exception of the Gas promoter, parent-specific 
methylation and are thus derived only from the non-methylated parental allele [5]. All 
alternative first exons are spliced onto the shared exons 2–13, giving rise to either coding 
(Gαs, XLαs, and NESP55), non-coding (AS), or presumably non-translated mRNAs (exon 
A/B).
The promoter region for the A/B transcript (GNAS A/B:TSS-DMR) is methylated on the 
maternal allele and its expression occurs only from the paternal allele. Likewise, the sense 
exon XL (GNAS-XL:Ex1-DMR) and the antisense exon AS (GNAS-AS1 :TSS-DMR) are 
methylated on the maternal allele and transcribed only from the paternal allele. Conversely, 
the exon coding for NESP55 shows methylation on the paternal allele (GNAS-NESP:TSS-
DMR) and its transcript is derived from the maternal allele.
PHP1B may follow an autosomal dominant pattern of inheritance (AD-PHP1B) or it can 
occur as a disorder that appears sporadically (spor-PHP1B). Loss-of-methylation (LoM) at 
GNAS A/B:TSS-DMR alone is found in AD-PHP1B cases caused either by microdeletions 
on the maternal allele comprising the gene encoding syntaxin 16 (STX16) [6–8], or by 
inversion of the region comprising exon A/B through exon 13 [9]. Copy numbers 
abnormalities encompassing one or several DMRs can affect the methylation patterns. For 
example maternal intragenic GNAS deletions including exon A/B to NESP55 DMR result in 
a paternal methylation pattern [10]. The four GNAS DMRs were also affected by deletions 
of AS exon 3–4 and/or NESP and AS 3–4 [6,8,11–13].
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Genomic DNA from spor-PHP1B patients show broad GNAS methylation changes 
including LoM at GNAS A/B:TSS-DMR, GNAS-XL:Ex1-DMR and GNAS-AS1 :TSS-
DMR promoter as well as gain of methylation (GoM) at GNAS-NESP:TSS-DMR [14]. So 
far, no specific genetic mutation has been identified as a cause of these changes.
Uniparental disomy (UPD) is a condition in which individual inherited both copies of one 
chromosome from only a single parent. Consequently, the patient harbors the parent-specific 
methylation pattern. Since the first description by Bastepe et al. [15], thirteen patients have 
been defined at the molecular level revealing a paternal disomy of chromosome 20 
(upd(20)pat) affecting either the entire chromosome or only the long arm (upd(20q)pat) [15–
22].
We now describe six new patients harboring upd(20)pat from a cohort of 33 patients affected 
by spor-PHP1B. One patient presented with a particularly mixed pattern of paternal iso- and 
heterodisomy at chromosome 20. Taken previous reports into consideration, we estimated 
the frequency of upd(20)pat in spor-PHP1B patients and defined a specific methylation 
signature. Last, we evaluated the influence of the parents’ childbearing ages on the 
occurrence of these epigenetic changes.
2. Subjects and methods
2.1. Patients
We studied 33 cases from Caucasian origin (17 males and 16 females) with the diagnosis of 
spor-PHP1B, who had been evaluated by our laboratory over the past 5 years. Data 
describing clinical symptoms were collected retrospectively using records from hospitals or 
primary care physicians. Routine biochemical assays were performed at the time of 
diagnosis, or during the follow up, in a variety of different clinical laboratories. This study 
analysis was conducted according to the Declaration of Helsinki with written consent for 
collection of DNA, clinical and laboratory data to conduct molecular studies obtained from 
the patient and/or their parents.
2.2. Molecular investigations
2.2.1. Methylation studies—Leukocyte genomic DNA was screened for GNAS 
mutations and STX16 deletions using procedures routinely used in the laboratory [13]. Copy 
number variants (CNV, such as deletions and duplications) and methylation profiling were 
assessed by methylation specific-multiplex ligation-dependent probe amplification (MS-
MLPA) assay using the ME031-A1 kit (MRC-Holland, Amsterdam, the Netherlands) 
[13,23] according to the manufacturer’s instruction. PCR products were analyzed on an 
ABI3130 sequencer using GeneMapper (Applied Biosystems) and Coffalyser (MRC-
Holland) softwares. The reproducibility of the assay was assessed by measuring the 
methylation at each DMR in a same control individual in eleven independent assays (Table 
S1), even if the reproducibility and reliability of the MS-MLPA assay were previously 
described by Elli et al. [24].
The diagnosis of spor-PHP1B was established on the basis of lack of a positive familial 
history, absence of CNV within STX16 or NESP, LoM at GNAS A/B:TSS-DMR, associated 
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to epigenetic changes at two or more DMRs including GNAS-XL:Ex1-DMR, GNAS-
AS1 :TSS-DMR as well as GoM at GNAS-NESP:TSS-DMR.
2.2.2. Uniparental disomy—Uniparental disomy was searched on DNA using two 
different procedures: array CGH and SNP genotyping. CGH/SNP array analysis (Agilent 
SurePrint G3 Cancer CGH + SNP 4×180K) was processed according to the manufacturer’s 
instruction (Agilent). One patient was also studied using a 300K SNP chip (CytoSNP-12 
Illumina®) which included 7614 markers (7598 SNPs and 16 CNVs) located on 
chromosome 20.
Thirty six specific SNP primers (listed in Fig. S2) were designed across chromosome 20 to 
build the chromosome 20 haplotypes. Briefly, the amplification refractory mutation system 
(ARMS)-PCR technique [25] was used to amplify the 36 SNPs using 7500 Fast Real-Time 
PCR System (Thermo Fisher Scientific) which allows single-plex SNP interrogation through 
fluorescence detection. Analysis of microsatellite markers across the 20q13.2 region was 
performed by the center of Human Genetic Research of the Massachusetts General Hospital 
as previously described [26]. Loss of heterozygosity (LoH) at each SNP indicates 
inheritance of two copies of the chromosome from one parent (isodisomy). Heterodisomy of 
chromosome 20 (hUPD) correspond to the inheritance of the two chromosomal homologs 
from one parent. It was searched in trio including the patient and both parental DNAs or in 
duo with only one parental DNA. Heterodisomy is inferred from allelic discordance between 
the patient and his/her mother or allelic concordance with his/her father. All genomic 
positions were based upon hg19/GRCh37 assembly.
2.3. Statistical analysis
For each biochemical parameter, differences between groups were calculated using the 
Mann and Whitney nonparametric U test for unpaired samples using GraphPadPrism 
software. A two-tailed p value < .05 was considered statistically significant.
3. Results
Clinical and biochemical data of the 33 patients diagnosed as spor-PHP1B are shown in 
Table S3. Depending of the degree of methylation defect at GNAS-XL:Ex1-DMR, patients 
can be subdivided in two major groups, one with a severe methylation defect (n = 25; < 
10%) and another with a partial methylation defect (n = 8; > 10%). The main clinical 
findings at presentation were convulsions associated with hypocalcemia and an elevated 
PTH level. Ten patients also had elevated TSH levels. Fifteen patients presented with mild 
AHO features as suggested by round face and slight metacarpal shortening. One patient 
(patient 6) for whom data were available exhibited a significant early-onset weight gain; the 
BMI had returned to normal before puberty (Fig. S4).
3.1. Upd(20)pat was identified in 6 patients (Figs. 1, 2 and Table S3, patients 1–6)
Four patients displayed complete upd(20)pat, one patient a upd (20q)pat (Fig. 1, patients 1 
and 2). Patient 6 harbors two paternal chromosomes 20, one of which had undergone mixed 
upd(20) rearrangement (Fig. 2). Analysis of DNA from this patient and his parents using a 
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300K SNP chip showed a LoH (paternal isodisomy, iUPD) extending from 20p13 to 20q13.2 
with telomeric paternal heterodisomy (hUPD). The SNP analysis indicated that the hUPD 
overlaps the GNAS locus at position 20q13.3. Finally, on 6 patients with upd(20) identified 
in this study, origin of parental disomy was determined only for two patients (paternal DNAs 
were available). Others upd(20)pat were inferred on the phenotype patient.
3.2. Percent of methylation at each GNAS DMRs was compared between spor-PHP1B 
patients with or without upd(20)pat (Fig. 3)
All patients with upd(20)pat display a complete loss of methylation of GNAS A/B:TSS-
DMR (0 ± 0%), negligible methylation at GNAS-AS1:TSS-DMR and GNAS-XL:Ex1-DMR 
(1.1 ± 1.6% and 0.77 ± 0.9%, respectively) and complete methylation at GNAS-NESP:TSS-
DMR (97 ± 3.3%) compare to normal control.
No statistical differences in the degree of methylation at GNAS-AS1 :TSS-DMR and GNAS 
A/B:TSS-DMR were observed between patients with or without upd(20)pat. Interestingly, 
we observed that spor-PHP1B patients without upd(20)pat displayed a broader range in the 
degree of methylation at GNAS-XL:Ex1-DMR [0–44%] compared to spor-PHP1B with 
upd(20)pat [0–2%], even if the threshold of significance is not reached (p = .11).
3.3. Parental age at conception in upd(20) (Fig. 4)
We compared parental ages at conception between spor-PHP1B patients with or without 
upd(20)pat and used as control AD-PHP1B patients from our laboratory (n = 17). We added 
to our data patients previously described with paternal and maternal upd(20) [15,18,21,27–
29]. The maternal age at conception was similar for AD-PHP1B and spor-PHP1B patients 
without upd(20)pat (26.7 ± 6.25 years, n = 17 vs. 26.7 ± 4.98, n = 20; p = .861). We 
observed a slightly higher in maternal age of conception in upd(20)pat patients (30.1 ± 6.24 
years, n = 8) even it is not statistically different from the other two groups (spor-PHP1B, p 
= .125 or AD-PHP1B, p = .186). By contrast, in upd(20)mat patients, maternal age at 
conception is statistically advanced compared to others groups and particularly to AD-
PHP1B group (38.1 ± 4.69 years; n = 15 vs. 26.7 ± 6.25, n = 17, p < .0001) [27–29]. The 
paternal age at conception was higher in upd(20)pat patients, but the difference is not 
statistically significant (30.9 ± 6.84 years, n = 7 vs. 28.7 ± 6.4, n= 15).
4. Discussion
This report presents clinical and biochemical data on a large cohort of patients with an 
imprinted disorder known as spor-PHP1B caused by methylation abnormalities at GNAS 
locus.
With respect to clinical implications, no significant differences were found in upd(20)pat 
patients compared with patients with methylation defect at GNAS locus of unknown origin. 
Clinical symptoms, mainly convulsion or seizure, develop at an age similar to other PHP1B 
patients [30]. Out of 17 patients with upd(20)pat in whom the data were available, six (35%) 
presented advanced weight (> +2 SD) for age at the time of diagnosis [15–18]. An intriguing 
feature remains the normalization of the weight after six years and indeed, Takatani et al. 
[21] reported that none other patients with upd(20)pat are obese at the age of 7 and 12, 
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respectively (Table 1). Patients with AD-PHP1B due to STX16 deletions and spor-PHP1B 
display very similar early overgrowth [31]. Recently, Gruters-Kieslich et al. [32] found 
obesity during the first year of life being the first clinical evidence for PHP1B suggesting 
that epigenetic GNAS analyses should be considered for unexplained obesity. Patients with 
upd(20) are therefore a good model to better understand the pathological mechanism 
responsible for the much-enhanced growth. With the exception of A/B transcript, our study 
brings arguments suggesting that the paternal transcripts which are biallelically expressed in 
spor-PHP1B with upd(20)pat and mono-allelically expressed in AD-PHP1B, cannot be 
responsible for the overgrowth in all forms of PHP1B patients. That restrains further 
investigations to the role of the defect of Gas expression and/or the biallelic expression of 
A/B.
UPD can involve either the whole chromosome and reflects complete isodisomy or affect the 
long arm of the chromosome 20 or be distal, from 20q13.13-qter [16,18]. It can be 
segmental, interspersed with regions of heterodisomy. In this study, we described a rare 
mixed chromosomal rearrangement associating paternal telomeric heterodisomy and 
paternal central isodisomy different from that previously described with different disomy 
breakpoint in the long arm [18]. The co-occurrence of meiotic recombination, abnormal 
segregation and subsequent correction are implicated [33].
We found that 18% of spor-PHP1B had inherited two copies of the paternal alleles at GNAS 
locus, a frequency closed to that reported by Fernandez-Rebollo et al. [18]. When combined 
with data from previous cohort reports [16,18,19,21], the frequency decreased to 13% (14 
with upd(20)pat among 105 spor-PHP1B, Table 1). In this study, we used SNP genotyping 
with high density arrays that detect blocks of homozygosity which offers a more reliable 
procedure than microsatellite markers with high informativity but limited density that can 
miss a small segmental UPD [17,18]. We have however to point out that the number of 
reported UPD cases could be a slight underestimate because heterodisomy could be missed 
in absence of parental samples.
Different technologies have been used to study the methylation at GNAS locus. Maupetit-
Mehouas et al. [34], Elli et al. [35] and Elli et al. [24] described complex LoM and GoM 
associations with complete and partial defects (pLoM) in spor-PHP1B. The overall 
frequency of upd(20) was low (8%) when searched considering both severe and partial loss 
of imprinting (pLoI) [35]. In the present paper we studied a cohort with the same MS-MLPA 
protocol which is currently used as a routine procedure for the quantification of the 
methylation defect at GNAS locus. In our cohort, severe methylation defects at all GNAS 
TSS-DMRs were only detected in upd(20)pat. Indeed, a broader range in the degree of 
methylation at GNAS-XL:Ex1-DMR is not in favour of upd(20). UPD might only be 
suspected in the presence of severe LoI especially GNAS-XL:Ex1-DMR. So, twenty five 
patients displayed severe methylation pattern (Table S3) and the upd(20)pat frequency 
reaches 24% when searching in this group.
The variation of methylation at GNAS-XL:Ex1-DMR remains without underlying genetic 
cause. A de novo mutation somewhere, within or not the GNAS domain that impacts on 
methylation establishment would not be excluded. In fact, mixed pattern of methylation 
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defects and pLoM at GNAS-XL:Ex1-DMR appear to be the most prevalent methylation 
pattern defect in spor-PHP1B [35]. Susceptibility to methylation defects has been described 
in multilocus imprinted disorders (MLID) [36,37] leading to the hypothesis of an imprinted 
gene network. Methylation defects in GNAS have been found in a subset of Beckwith-
Wiedemann syndrome (BWS) cases [38], and the presence of PHP1B in BWS patients has 
been described, at least, once [39]. Finally, sporadic cases of PHP1B with pLoI could 
represent true stochastic errors in early post-zygotic phases and embryonic maintenance of 
methylation [40] and might correspond to mosaicism [24].
The identification of a genetic cause allows adapted genetic counseling for the affected 
patient and their families. With a prevalence estimated to be approximately 1.65/10000 [41], 
UPD is a rare condition resulting from meiotic nondisjunction followed by compensatory 
mechanisms including trisomic rescue, monosomic rescue, compensatory UPD and/or 
somatic recombination errors [42]. No case of recurrence has been reported until now. A 
reassuring genetic counseling can be brought to the family for prenatal diagnosis.
Last, our study does not show a correlation between paternal or maternal ages at the 
conception and the occurrence of upd(20)pat in their child. In contrast an advanced maternal 
age is clearly associated to upd(20)mat [27–29,43,44]. Incidence of aneuploidie in oocytes 
increased with maternal age at childbirth and would contribute to the development of 
trisomy rescue type maternal UPD or monosomy rescue type paternal UPD by replication of 
a single paternally derived chromosome [45]. The lack of connection with parental age 
suggests upd (pat) to be a random event during the formation of reproductive cells (eggs and 
sperm).
In conclusion, our study emphasizes the high frequency of upd(20) pat in spor-PHP1B 
patients. Methylation profiling using MS-MLPA is a convenient tool for evaluating the 
methylation pattern at GNAS locus to better define the phenotype of spor-PHP1B patients 
who should benefit of genetic screening for upd(20)pat. While upd(20)mat is strongly 
associated with an advanced maternal childbearing age, the upd(20)pat occurrence is not 
linked to the parental age at the conception.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
CGH/SNP-array in two patients presenting upd(20)pat (patient 1) or upd(20q)pat (patient 2). 
A: copy number, the X-axis represents the normalized log2 ratio Cy5(patient)/Cy3(healthy 
control) fluorescence intensity thresholds – 1 (loss) and 1 (gain), while the Y-axis represents 
the chromosome 20; B: SNP array; each SNP probe (represented by a filled circle) at a given 
locus can exist either in homozygous state (a single allele at 0 or 2) or in heterozygous state 
(at 1). Homozygosity is demonstrated by probes present at either 0 or 2 and the absence of 
probes at 1.
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Fig. 2. 
Mixed rearrangement in chromosome 20 (patient 6).
upd(20)pat.arr[GRCh37] 20p13(63244_1792434)x2 htz,20p13q13.2(1800783_51758074)x2 
hmz, 20q13.2q13.33(51763379_62909908)x2 htz. A. The inferred breakpoints between 
paternal isodisomy (iUPD) and paternal heterodisomy (hUPD) are indicated by the two-way 
arrows: in the short arm, they are located between the last heterozygous SNP (rs58532) 
(chr20:g.1792434) and the first homozygous one rs156330 (chr20:g.1826095) and in the 
long arm between rs2904295 (chr20:g.51677970) and rs6126764 (chr20:g.51763379).
B. SNP (single nucleotide polymorphism) and microsatellite markers analysis in patient 6 
confirmed mixed rearrangement with paternal isodisomy (iUPD) extending from 20p13 to 
20q13.2 with telomeric paternal heterodisomy (hUPD)(grid). Arrows indicate informative 
SNPs or microsatellite markers. The hUPD overlaps the GNAS locus at position 20q13.3.
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Fig. 3. 
Methylation pattern (%) at GNAS locus in patients with spor-PHP1B with or without 
upd(20)pat.
Dosage and differential methylation analyses were assessed by multiplex ligation-dependent 
probe amplification and methylation specific-MLPA (MS-MLPA). The relative peak area of 
each target probe from the ligation-only reaction of the patient DNA was compared to that 
obtained from the controls. Data are expressed as percentage of methylation (mean ± SD) 
for each DMRs. The percentage was 50 in the control for the DMRs in which allele-specific 
methylation was observed. A percentage closed to 100 suggests biallelic methylation. In 
contrast, a value closed to 0 suggests biallelic demethylation at these DMRs. p values for 
comparison between groups are indicated. ns: no significance.
Colson et al. Page 13
Bone. Author manuscript; available in PMC 2019 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. 
Maternal and paternal age at conception in patients with spor-PHP1B with and without 
UPD.
Circles display maternal age (A) and squares paternal age (B) respectively. Empty form: 
control patient (AD-PHP1B); form with a point: spor-PHP1B without upd(20) pat; half full 
form (literature [15,18,21]) and full form (this study): spor-PHP1B due to upd(20)pat; form 
with a cross: upd(20)mat (literature [24,27]). N = number of subjects per group. The 
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horizontal and vertical bars for each group represent the mean ± SD. p values for 
comparison between groups are indicated; y: years.
Colson et al. Page 15
Bone. Author manuscript; available in PMC 2019 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Colson et al. Page 16
Ta
bl
e 
1
Cl
in
ic
al
 a
nd
 e
pi
ge
ne
tic
s f
ea
tu
re
s w
ith
 p
ar
en
ta
l a
ge
 a
t c
on
ce
pt
io
n 
of
 p
at
ie
nt
s w
ith
 sp
or
-
PH
P1
B 
du
e 
to
 u
pd
(20
)pa
t r
ep
ort
ed
 in
 th
e l
ite
rat
ure
 an
d c
om
pa
ris
on
 w
ith
 ou
r p
ati
en
ts.
 up
d(2
0)p
at:
 pa
ter
na
l d
iso
my
 at
 
ch
ro
m
os
om
e 
20
; N
D
: n
ot
 d
et
er
m
in
at
ed
.
A
ut
ho
rs
B
as
te
pe
 e
t a
l. 
[1
5]
Le
cu
m
be
rri
 e
t a
l. 
[2
2]
B
as
te
pe
 e
t a
l. 
[1
6]
Fe
rn
an
de
z-
Re
bo
llo
 e
t a
l. 
[1
8]
D
ix
it 
et
 a
l. 
[1
7]
Pa
tie
nt
 1
Pa
tie
nt
 2
Pa
tie
nt
 3
Pa
tie
nt
 4
Pa
tie
nt
 1
Pa
tie
nt
 2
Fr
eq
ue
nc
y
Ca
se
 re
po
rt
Ca
se
 re
po
rt
1/
22
 (4
.5%
)
4/
20
 (2
0%
)
Ca
se
s r
ep
or
ts
U
pd
(20
)pa
t ty
pe
U
pd
(20
q)
U
pd
(20
q)
U
pd
(20
)
U
pd
 (2
0q
13
.13
-qt
er)
iU
PD
(20
q)
H
U
PD
(20
p),
 iU
PD
 +p
uta
tiv
e 
H
U
PD
 (2
0) 
(q1
3.3
3q
23
)
U
pd
(20
q1
3.1
3-q
ter
)
U
pd
(20
q1
2-q
13
.33
-qt
er)
U
pd
(20
q1
3.3
1-q
13
.32
)
M
et
ho
d
ST
R
ST
R
SN
Ps
 +
 1
00
K
SN
P 
ar
ra
y
ST
R,
 S
N
P 
ar
ra
y
ST
R 
an
al
ys
is;
SN
P 
ar
ra
y
GN
A
S 
TS
S-
D
M
Rs
 m
et
hy
la
tio
n 
an
al
ys
is
M
et
hy
la
tio
n-
se
ns
iti
v
e 
re
st
ric
tio
n 
en
zy
m
e
M
S-
M
LP
A
N
D
M
S-
M
LP
A
M
et
hy
la
tio
n-
sp
ec
ifi
c 
PC
R
GN
A
S-
NE
SP
: T
SS
-D
M
R
G
oM
GN
A
S-
AS
 1
: T
SS
-D
M
R
Lo
M
GN
A
S-
XL
: E
x1
-D
M
R
Lo
M
GN
A
S 
A/
B:
TS
S-
D
M
R
Lo
M
Se
x
M
M
F
F
M
M
M
M
M
A
ge
 a
t d
ia
gn
os
is 
(ye
ars
)
5
9
3.
5
26
9
5
46
14
.5
5.
5
W
ei
gh
t a
t b
irt
h 
(pe
rce
nti
le)
N
D
50
–7
5
25
–5
0
W
ei
gh
t a
t d
ia
gn
os
is 
(S
D)
+
 3
.4
−
1
+
 2
−
0.
1
−
0.
92
+
 5
.5
+
 1
.5
+
 0
.7
5
+
 2
H
ei
gh
t a
t d
ia
gn
os
is 
(S
D)
+
 3
.6
−
2
>
 +
 2
−
1
−
1.
6
+
 2
−
2
0
−
2
A
H
O
 si
gn
s
−
+
−
−
+
−
N
D
−
N
D
M
at
er
na
l a
ge
 a
t c
on
ce
pt
io
n 
(ye
ars
)
39
N
D
27
31
33
N
D
Pa
te
rn
al
 a
ge
 a
t c
on
ce
pt
io
n 
(ye
ars
)
N
D
27
32
33
N
D
A
ut
ho
rs
Ta
ka
ta
ni
 e
t a
l. 
[2
1]
Pa
rk
 e
t a
l. 
[2
0]
Jin
 e
t a
l. 
[1
9]
Th
is 
pa
pe
r
Pa
tie
nt
 1
Pa
tie
nt
 2
1
2
3
4
5
6
Fr
eq
ue
nc
y
2/
23
 (8
,7%
)
Ca
se
 re
po
rt 
os
te
os
ar
co
m
a
1/
7 
(14
%)
6/
33
 (1
8.2
%)
U
pd
(20
)pa
t ty
pe
U
pd
(20
q)
U
pd
(20
q)
U
pd
(20
q)
U
pd
(20
)
U
pd
(20
q)
U
pd
(20
)
U
pd
(20
)
U
pd
 (2
0)
M
ix
ed
 H
U
PD
/iU
PD
M
et
ho
d
SN
Ps
 G
NA
S 
+ 
ST
R
ST
R
ST
R
CG
H
/S
N
P 
ar
ra
y
ST
R 
+ 
SN
P 
ar
ra
y
GN
A
S 
TS
S 
D
M
Rs
 m
et
hy
la
tio
n 
an
al
ys
is
M
S-
M
LP
A
GN
A
S-
NE
SP
: T
SS
-D
M
R
G
oM
97
%
91
%
10
1%
97
%
98
%
95
%
GN
A
S-
AS
 1
: 
TS
S-
D
M
R
Lo
M
0%
0%
0%
3%
3%
0%
GN
A
S-
XL
: E
x1
-D
M
R
Lo
M
0%
0%
1%
2%
2%
0%
Bone. Author manuscript; available in PMC 2019 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Colson et al. Page 17
GN
A
S 
A/
B:
TS
S-
D
M
R
Lo
M
0%
0%
0%
0%
0%
0%
Se
x
M
F
M
M
F
M
M
F
F
M
A
ge
 a
t d
ia
gn
os
is 
(ye
ars
)
12
7
21
8
33
42
N
D
27
.5
10
4
W
ei
gh
t a
t b
irt
h 
(pe
rce
nti
le)
N
D
>
 9
0
N
D
75
−9
0
10
50
–7
5
W
ei
gh
t a
t d
ia
gn
os
is 
(S
D)
+
 0
.6
+
 1
.2
−
1
+
 1
+
 0
.5
>
 +
3
N
D
0
+
 3
H
ei
gh
t a
t d
ia
gn
os
is 
(S
D)
+
 1
.5
+
 1
.2
−
1.
5
+
 0
.4
5
−
1
+
 0
.5
N
D
−
1.
5
+
 1
0
Sy
m
pt
om
s o
f A
H
O
−
−
−
−
−
−
N
D
+
−
−
M
at
er
na
l a
ge
 a
t c
on
ce
pt
io
n 
(ye
ars
)
30
N
D
19
N
D
36
26
Pa
te
rn
al
 a
ge
 a
t c
on
ce
pt
io
n 
(ye
ars
)
28
N
D
22
N
D
44
30
Bone. Author manuscript; available in PMC 2019 July 18.
